MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Recursion Pharmaceuticals Inc

Închisă

SectorSănătate

5.83 5.62

Rezumat

Modificarea prețului

24h

Curent

Minim

5.52

Maxim

6.21

Indicatori cheie

By Trading Economics

Venit

-24M

-202M

Vânzări

10M

15M

Marjă de profit

-1,373.259

Angajați

800

EBITDA

-26M

-191M

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

+15.96% upside

Dividende

By Dow Jones

Următoarele câștiguri

7 aug. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-27M

2.3B

Deschiderea anterioară

0.21

Închiderea anterioară

5.83

Sentimentul știrilor

By Acuity

67%

33%

339 / 376 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

Recursion Pharmaceuticals Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

17 iul. 2025, 23:34 UTC

Achiziții, Fuziuni, Preluări

FTC Reopens Consent Orders for Proposed Acquisitions from Exxon Mobil, Chevron

17 iul. 2025, 21:14 UTC

Achiziții, Fuziuni, Preluări

Basel Medical Group Puts $1 Billion Bitcoin Purchase on Hold

17 iul. 2025, 21:04 UTC

Principalele dinamici ale pieței
Achiziții, Fuziuni, Preluări

Norfolk Southern Shares Rise on WSJ Report of Union Pacific Acquisition Interest

17 iul. 2025, 23:43 UTC

Market Talk

Gold Edges Higher on Possible Position Adjustments -- Market Talk

17 iul. 2025, 23:42 UTC

Market Talk

Nikkei May Rise on Signs of U.S. Econ Strength -- Market Talk

17 iul. 2025, 22:47 UTC

Achiziții, Fuziuni, Preluări

FTC: Maintaining Restrictions for Former Pioneer CEO Scott Sheffield Would Damage FTC's Credibility

17 iul. 2025, 22:46 UTC

Achiziții, Fuziuni, Preluări

Potential Rail Merger Could Prompt Berkshire Hathaway to Bid for CSX -- Barrons.com

17 iul. 2025, 22:46 UTC

Achiziții, Fuziuni, Preluări

FTC Also Says Exxon Order Disregarded Guidelines and Precedent

17 iul. 2025, 22:43 UTC

Achiziții, Fuziuni, Preluări

FTC: Maintaining Restrictions on John Hess's Employment Would 'Damage the FTC's Credibility'

17 iul. 2025, 22:43 UTC

Achiziții, Fuziuni, Preluări

FTC: Chevron Order Disregarded FTC Merger Guidelines and Decades of Precedent

17 iul. 2025, 22:40 UTC

Achiziții, Fuziuni, Preluări

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

17 iul. 2025, 22:40 UTC

Achiziții, Fuziuni, Preluări

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

17 iul. 2025, 22:30 UTC

Market Talk
Câștiguri

Netflix Sticks to Its Playbook as Competitive Landscape Changes -- Market Talk

17 iul. 2025, 22:20 UTC

Market Talk
Câștiguri

Global Equities Roundup: Market Talk

17 iul. 2025, 22:20 UTC

Market Talk
Câștiguri

Netflix Focusing Resources on TV Viewers It Hasn't Yet Captured -- Market Talk

17 iul. 2025, 22:04 UTC

Market Talk
Câștiguri

Netflix Redesign Done to Match Current Capabilities -- Market Talk

17 iul. 2025, 22:03 UTC

Achiziții, Fuziuni, Preluări

China Threatens to Block Panama Ports Deal Unless Its Shipping Giant Is Part of It -- 2nd Update

17 iul. 2025, 21:58 UTC

Market Talk
Câștiguri

Netflix Internal Data Doesn't Indicate Weaker Consumer Sentiment -- Market Talk

17 iul. 2025, 21:57 UTC

Câștiguri

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

17 iul. 2025, 21:47 UTC

Câștiguri

Netflix Raises Revenue, Margin Forecasts After Strong Second Quarter -- Update

17 iul. 2025, 21:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 iul. 2025, 21:45 UTC

Market Talk

Crypto Bills Welcomed by Venture Capital, Trade Group Says -- Market Talk

17 iul. 2025, 21:38 UTC

Achiziții, Fuziuni, Preluări

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- 2nd Update

17 iul. 2025, 21:22 UTC

Achiziții, Fuziuni, Preluări

Update: Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

17 iul. 2025, 21:05 UTC

Câștiguri

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

17 iul. 2025, 21:04 UTC

Achiziții, Fuziuni, Preluări

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- Update

17 iul. 2025, 21:02 UTC

Achiziții, Fuziuni, Preluări

Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

17 iul. 2025, 20:59 UTC

Achiziții, Fuziuni, Preluări

Basel Medical Group Puts $1B Bitcoin Purchase on Hold

17 iul. 2025, 20:50 UTC

Market Talk
Câștiguri

Tech, Media & Telecom Roundup: Market Talk

17 iul. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

Comparație

Modificare preț

Recursion Pharmaceuticals Inc Așteptări

Obiectiv de preț

By TipRanks

15.96% sus

Prognoză pe 12 luni

Medie 6.25 USD  15.96%

Maxim 8 USD

Minim 4 USD

În baza a 5 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruRecursion Pharmaceuticals Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

5 ratings

1

Cumpărare

4

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

4.15 / 4.75Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Bearish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

339 / 376 Clasament în Sănătate

Sentimentul știrilor

Evidențe de scădere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.